Heather Bresch, Mylan CEO (Getty Images)
Mylan wins early FDA OK of a Tecfidera knockoff, and they're launching with an eye to toppling Biogen's blockbuster franchise
Biogen $BIIB just lost control of its cash cow franchise.
On Tuesday, analysts were quick to notice that the FDA had flagged a full approval …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
